Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 18th.
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) last issued its quarterly earnings data on Monday, May 23rd. The company reported ($2.50) earnings per share (EPS) for the quarter. On average, analysts expect Quoin Pharmaceuticals to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Get Quoin Pharmaceuticals alerts:Quoin Pharmaceuticals Stock Down 1.3 %
Shares of QNRX stock opened at $4.72 on Tuesday. Quoin Pharmaceuticals has a 52-week low of $3.58 and a 52-week high of $444.00. The company has a 50-day simple moving average of $5.87 and a two-hundred day simple moving average of $11.07.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Quoin Pharmaceuticals stock. Virtu Financial LLC bought a new position in Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 42,665 shares of the company's stock, valued at approximately $57,000. Virtu Financial LLC owned approximately 0.51% of Quoin Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 21.72% of the company's stock.Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on QNRX shares. LADENBURG THALM/SH SH started coverage on shares of Quoin Pharmaceuticals in a research report on Friday, May 6th. They issued a "buy" rating and a $25.00 price objective for the company. Maxim Group reduced their target price on shares of Quoin Pharmaceuticals to $25.00 in a research report on Thursday, May 26th.
About Quoin Pharmaceuticals
(Get Rating)
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.
See Also
- Get a free copy of the StockNews.com research report on Quoin Pharmaceuticals (QNRX)
- MarketBeat Podcast: ESG – Profitably Invest Your Values
- Is Uber Bait and Switching Its Way to Profitability?
- Is Ford About To Crush Workhorse Group?
- Is it Time to Throw in the Towel On Coinbase Stock?
- The Five Hottest Calls From The Q2 Earnings Season
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.